Calton & Associates’s Insys Therapeutics, Inc. INSY Stock Holding History

Calton & Associates’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-200	Closed	-$2K	–	1451
2017 Q4	$2K	Buy	+200	New	+$1.31K	﹤0.01%	1420

Other funds holding INSY

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Calton & Associates's INSY Position: Q1 2018 in Review

Calton & Associates sold out of Insys Therapeutics, Inc. (INSY) in Q1 2018, closing a stake of 200 shares — an estimated $2K sold.

Calton & Associates first reported a position in INSY in Q4 2017 and held it in 1 quarter. The position peaked at $2K in Q4 2017. 110 funds tracked by Wall St. Rank hold INSY as of Q1 2018.

Calton & Associates reported no remaining Insys Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Calton & Associates sold 200 Insys Therapeutics, Inc. shares in Q1 2018, an estimated $2K.
Calton & Associates first reported a position in Insys Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
Calton & Associates's Insys Therapeutics, Inc. position peaked at $2K in Q4 2017.
110 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.